Muse Cell Physicians in the United States: How to Verify Who Is Actually Qualified
Medically reviewed by Dr. Charles Pereyra, MD — Medical Director, Springs Rejuvenation. Last reviewed October 22, 2026.
Written by the Springs Rejuvenation regenerative medicine team from direct clinical experience administering stem cell and exosome protocols at our Aventura, Miami center.
Muse cells—multilineage-differentiating stress-enduring cells—represent a specific subset of pluripotent-like cells first characterized by Kuroda, Dezawa and colleagues in 2010. Unlike the broad umbrella of "stem cell therapy" marketed by hundreds of clinics, Muse cells are defined by a specific surface marker (SSEA-3+) and a unique ability to tolerate stress and home to damaged tissue when delivered intravenously. As interest grows in this investigational approach, patients face a crowded field in which verifiable physician qualifications vary widely. This guide explains how to evaluate top physicians offering Muse cell therapy in the United States using objective, checkable criteria rather than marketing claims.
What Makes Muse Cell Therapy Different from General Stem Cell Marketing
Muse cells were first isolated from human bone marrow, adipose tissue, and dermal fibroblasts by Wakao, Dezawa and colleagues in 2011, who demonstrated that these SSEA-3-positive cells could differentiate into cells representing all three germ layers. This pluripotent-like capacity distinguishes Muse cells from the mesenchymal stem cells (MSCs) or stromal vascular fraction (SVF) offered by many regenerative clinics. The published literature on Muse cells is small but growing, centered largely on work from Japanese investigators.
Yamada and colleagues (2018) identified a molecular guidance system—the sphingosine-1-phosphate receptor 2 (S1P–S1PR2) axis—that appears to direct intravenously delivered Muse cells toward sites of tissue injury in preclinical models. This homing mechanism is the scientific rationale for intravenous delivery, in contrast to local injection protocols common in other regenerative approaches. Individual responses vary, and the translation of preclinical findings to human outcomes remains under investigation.
A first-in-human Japanese safety study (Noda and colleagues, 2020) evaluated intravenous delivery of a Muse cell product designated CL2020 in a small cohort. The trial's primary aim was safety assessment, not efficacy, and the published results reported no serious adverse events directly attributable to the cells over the follow-up period. This early-stage work laid the groundwork for subsequent controlled trials.
A randomized, double-blind Japanese trial (Niizuma and colleagues, 2023) tested CL2020 in a different clinical context. The primary endpoint showed a modest effect, and individual responses varied. The published data are not uniformly positive—a reflection of the investigational nature of this field. These nuances matter when evaluating provider claims: a physician who accurately describes the evidence, including its limitations, demonstrates scientific literacy that vague promises of "miraculous results" do not.
Why Physician Supervision Matters in Regenerative Medicine
Regenerative medicine exists in a regulatory gray zone. The FDA has not approved Muse cell products for commercial use in the United States, and any administration of such cells occurs under research protocols or as an investigational therapy. This regulatory reality makes physician oversight critical. A physician who discloses that Muse cell therapy is not FDA approved, who reviews the patient's medical history and imaging, and who explains both the published evidence and its gaps is practicing within an ethical framework. Conversely, providers who promise certain outcomes or who delegate candidacy decisions to sales staff raise immediate credibility questions.
Dr. Charles Pereyra, MD, a board-certified emergency medicine physician with residency training at NewYork-Presbyterian Brooklyn Methodist Hospital and medical school at Weill Cornell Medical College, conducts all candidacy evaluations personally. His approach includes review of prior imaging (MRI, X-ray, or ultrasound), laboratory work when relevant, and a detailed conversation about what the investigational literature does and does not show. This physician-led screening is standard in academic settings but less common in the commercial regenerative space.
Patients considering top physicians offering Muse cell therapy in the United States should verify that a licensed physician—not a nurse practitioner, physician assistant, or wellness consultant—performs the intake assessment, explains the consent process, and remains available for follow-up. The National Provider Identifier (NPI) registry and state medical board websites allow patients to confirm a physician's licensure, board certification status, and disciplinary history within minutes.
How to Verify a Provider's Credentials and Training
Marketing websites often use phrases like "leading expert" or "top-rated clinic" without offering checkable facts. Here is a practical verification checklist:
- Board certification: Confirm the physician holds current certification from the American Board of Medical Specialties (ABMS) in a relevant field—emergency medicine, physical medicine and rehabilitation, orthopedics, or dermatology, for example. Board certification requires passing rigorous examinations and, in most specialties, ongoing recertification.
- Published research or presentations: Search PubMed or Google Scholar for the physician's name. Peer-reviewed publications or presentations at scientific meetings (American Academy of Regenerative Medicine, International Society for Stem Cell Research) indicate engagement with the evidence base. Dr. Charles Pereyra has three indexed publications and is a member of the International Society of Hair Restoration Surgery (ISHRS), reflecting ongoing participation in the professional community.
- Transparent consent process: Ask whether the clinic provides a written informed-consent document that states the therapy is investigational and not FDA approved. Ethical practice requires this disclosure.
- Uncertain outcomes: Any provider who promises specific results—"90% improvement," "certain regrowth," "complete resolution"—is either uninformed or dishonest. The published Muse cell literature does not support such certainty. Look instead for language like "individual responses vary" and "early-stage evidence."
- US-based access: Patients historically traveled to Japan, Mexico, or Colombia for investigational cell therapies. The availability of physician-supervised Muse cell therapy in the United States eliminates the logistical burden and legal ambiguity of medical tourism.
Top physicians offering Muse cell therapy in the United States will welcome these questions. Evasive or defensive responses are a warning sign.
The Evidence Base: What Published Studies Show (and Don't Show)
The Muse cell literature comprises fewer than two dozen peer-reviewed papers, most authored by the Japanese research groups that pioneered the field. This is a young area of science, and honest communication requires acknowledging both what is known and what remains uncertain.
Hare and colleagues (2009) published a randomized trial of intravenous allogeneic mesenchymal stem cells in a different clinical application. The study's primary aim was safety, and the investigators reported no increase in adverse events in the cell-supported group compared with placebo. This work, while not specific to Muse cells, established a foundation for the safety profile of intravenous stem cell delivery.
Bartolucci and colleagues (2017) conducted the RIMECARD trial, which tested umbilical-cord-derived MSCs in patients with chronic conditions. The trial reported a mean improvement of approximately seven points in left ventricular ejection fraction at one year, a modest but statistically significant finding. Individual responses varied, and longer-term data remain limited. Again, while not Muse-specific, this trial informs the broader context in which investigational cell therapies are evaluated.
In the context of hair restoration, Gentile and Garcovich (2019) published a systematic review of platelet-rich plasma for androgenetic alopecia, summarizing data from multiple small trials. The review concluded that PRP may offer benefit in select cases, but individual responses are highly variable and the field lacks large, high-quality randomized trials. Shin and colleagues (2015) explored adipose-derived stem cell conditioned media in a small study of alopecia, reporting preliminary positive signals but noting the need for larger confirmatory work. These hair-focused papers illustrate a recurring theme: early-stage evidence is suggestive, not definitive.
What does the evidence not show yet? Muse cell therapy has not been validated in large, multi-center, placebo-controlled trials in the United States. Long-term safety data beyond one to two years are sparse. The optimal cell dose, delivery schedule, and patient selection criteria remain under investigation. No peer-reviewed publication supports the claim that Muse cells are a substitute for conventional medical or surgical interventions in any condition. Patients deserve to hear this honest assessment before making a financial commitment.
Who Is Not a Candidate for Muse Cell Therapy
Physician-led screening means that not every applicant is accepted for therapy. Dr. Pereyra declines to proceed when the patient's medical history, imaging findings, or expectations suggest that investigational cell therapy is unlikely to be appropriate. This selectivity—uncommon in the commercial regenerative space—is a marker of ethical practice.
Examples of scenarios in which a physician might recommend against Muse cell therapy include:
- Active infection or uncontrolled inflammatory disease at the proposed intervention site
- Unrealistic expectations that cannot be recalibrated through education about the evidence
- Imaging that shows structural damage beyond the plausible scope of cellular repair (such as bone-on-bone joint degeneration with complete cartilage loss)
- Medical comorbidities that substantially elevate procedural risk
- Financial hardship that would make the investigational therapy a disproportionate burden
The screening conversation typically includes review of any prior imaging (MRI, X-ray), discussion of current medications and allergies, and a detailed explanation of what the published literature does and does not demonstrate. Patients who proceed do so with informed consent, understanding that individual responses vary and that this therapy remains investigational.
Accessing Physician-Led Muse Cell Therapy in the United States
For patients evaluating top physicians offering Muse cell therapy in the United States, the logistical advantages of domestic access are significant. Medical tourism to Japan, where much of the original Muse cell research occurred, involves visa requirements, language barriers, travel costs, and the challenge of coordinating follow-up care across international borders. Accessing physician-supervised therapy in Miami, New York, Los Angeles, Austin, or Atlanta eliminates these obstacles.
The absence of FDA approval means that Muse cell therapy in the United States is delivered as an investigational service, not a standard-of-care option. Patients should expect transparent pricing (investigational therapies are rarely covered by insurance), a detailed informed-consent process, and realistic counseling about both the potential benefits and the acknowledged gaps in the evidence. Springs Rejuvenation, where Dr. Pereyra practices, follows this model: physician-led evaluation, evidence-based counseling, and written disclosure that the therapy is not FDA approved.
Patients considering this approach are encouraged to ask detailed questions, request time to review the consent documents, and consult with their primary care physician or specialist before proceeding. The decision to pursue investigational therapy should be informed, unhurried, and grounded in an accurate understanding of the science.
What Credentials Should a Muse Cell Physician Hold?
At minimum, look for current board certification in a relevant medical specialty, an active state medical license with no disciplinary actions, and evidence of engagement with the regenerative medicine literature—either through published research, conference presentations, or membership in professional societies such as the International Society for Stem Cell Research or the American Academy of Regenerative Medicine. The physician should be willing to provide their National Provider Identifier (NPI) number, which you can verify through the national registry. Transparency about training and credentials is the baseline expectation; evasiveness is a red flag.
What Does the Evidence NOT Show Yet?
The published Muse cell literature does not yet include large, multi-center, placebo-controlled trials conducted in the United States. Long-term safety and efficacy data beyond two years are limited. The optimal patient selection criteria, cell dose, and delivery protocol remain areas of active investigation. No peer-reviewed study demonstrates that Muse cell therapy is superior to conventional medical or surgical options for any specific condition. The field is investigational, and individual responses vary widely. A physician who acknowledges these gaps is practicing evidence-based medicine; one who glosses over them is not.
How Does a Physician Determine if Someone Is a Candidate?
Candidacy evaluation begins with a detailed medical history, including any prior interventions, current medications, allergies, and relevant imaging studies such as MRI or X-ray. The physician reviews this information to assess whether the patient's anatomy and health status fall within the parameters studied in the published literature. A candid conversation about expectations follows: patients who understand that individual responses vary and that the therapy is investigational are more likely to be satisfied. If the physician concludes that the patient's condition is unlikely to respond, or that risks outweigh potential benefits, the ethical path is to recommend against proceeding. This selectivity distinguishes physician-led programs from sales-driven clinics.
Can Muse Cell Therapy Replace Conventional Medical Care?
No. Muse cell therapy is investigational and should be considered as a complement to, not a replacement for, standard medical and surgical options. Patients with serious or progressive conditions should continue to work with their primary care physician or specialist. The published evidence does not support the idea that Muse cells are a stand-alone solution for any disease. Physicians who frame investigational cell therapy as a last-resort option after conventional approaches have been exhausted—or as an adjunct to ongoing care—are practicing within the bounds of the current evidence. Those who suggest that Muse cells can replace established therapies are making unsupported claims.
At Springs Rejuvenation, stem cell and exosome therapies are used together as part of a personalized regenerative protocol.
Medical Disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Springs Rejuvenation processes exosomes in an FDA approved lab. Individual results may vary. This content is reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director of Springs Rejuvenation, and is provided for educational purposes only. Always consult a qualified physician.